Diabetes Devices and Drugs: North America Guides Global Market at a 5.9% CAGR from 2013 to 2019 A global surge in diabetic population, coupled with technological innovations and extensive R&D activities, has boosted the worldwide market for diabetes devices and drugs, according to a report published by Transparency Market Research.The report, titled “Diabetes Devices and Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019�, indicates that registering a CAGR of 5.9% from 2013 to 2019, the global diabetes devices and drugs market is likely to grow from US$54.04 billion in 2012 to US$83.0 billion in 2019.
Diabetes is a group of metabolic disorders in which pancreas is not able to produce enough insulin (sugar metabolizing hormone) (type-1) or the body develops a resistance to produce insulin and is not able to utilize the produced insulin (type-2). This condition triggers various malignancies and diseases. Diabetes market is a consolidated market and the demand for various advanced devices and medicines is increasing steadily, owing to exponential growth in the prevalence of diabetes across the globe. This report is focused towards identifying the current scenario as well as the future market potential for diabetes drugs and devices globally. The global diabetes devices and drugs market is segmented into two segments, namely; diabetes devices and diabetes drugs class. Diabetes devices segment is divided into diabetes diagnostic and monitoring devices and insulin delivery devices. Diabetes diagnostic and monitoring devices class is further split into analog glucose meters, test strips, lancets and lancing devices, CGM devices and others. Insulin delivery devices class is divided into insulin pens, insulin syringes, insulin pumps and insulin injectors. The second segment of the market, that is, drugs class is fragmented into insulin derivatives, oral anti-diabetes drugs (OADs) and non insulin injectable anti-diabetes drugs. Insulin derivatives are categorized on the basis of their time of action, such as, rapid-acting, short-acting, intermediate-acting, long-acting and premixed insulin derivatives. Oral antidiabetes drugs are divided into sulphonylureas, biguanides, meglitinides, alpha glucosidase inhibitors, thiazolidinediones, DPP-IV inhibitors, and SGLT2 inhibitors. GLP-1 agonists represent the injectable anti-diabetes drugs class. The report also provides in-depth analysis of pipeline diabetes drugs.